FierceBiotechFierceBiotechResearchFierceBiotechITFierceVaccinesFiercePharmaFiercePharmaManufacturing   FierceHealthcare

Catalyst Biosciences - Top 20 VC deals of 2008

Tools

Catalyst Biosciences, FierceBiotech's top venture capital deals of 2008Company: Catalyst Biosciences
Based: South San Francisco, CA
Amount: $40.28M

Investors: Johnson & Johnson Development Corporation, Undisclosed Venture Firm, Essex Woodlands Health Ventures, Burrill & Company, Novartis Venture Fund, HealthCare Ventures, Morgenthaler Ventures, Sofinnova Ventures

Scoop: Catalyst programs redirect protein-degrading enzymes (called Alterases) to degrade specific proteins that promote disease. It's third round of funding, raised in December, gave the company cash to build its pipeline of Alterase therapeutics. Catalyst is advancing its lead protease, CB 813, an improved factor VIIa product for the treatment of acute bleeding in hemophiliacs, through Phase I/II proof-of-concept studies in patients.

Bookmark and Share
Get Your FREE FierceBiotech Email Newsletter:
Be the first to comment
More stories about Catalyst Biosciences   Biotech Venture Capital  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

To combat spam, please enter the code in the image.